100 related articles for article (PubMed ID: 22212564)
1. Editorial: Towards the eradication of hepatitis C virus.
Marcellin P; Asselah T
Liver Int; 2012 Feb; 32 Suppl 1():1. PubMed ID: 22212564
[No Abstract] [Full Text] [Related]
2. Serine protease inhibitors as anti-hepatitis C virus agents.
Reiser M; Timm J
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
[TBL] [Abstract][Full Text] [Related]
3. Trial watch: Protease inhibitors show promise against HCV.
Nat Rev Drug Discov; 2009 Jan; 8(1):11. PubMed ID: 19116621
[No Abstract] [Full Text] [Related]
4. Boceprevir.
Maddur H; Kwo PY
Hepatology; 2011 Dec; 54(6):2254-7. PubMed ID: 22095684
[No Abstract] [Full Text] [Related]
5. [Studies with boceprevir].
MMW Fortschr Med; 2011 Jul; 153(29-31):16. PubMed ID: 21830728
[No Abstract] [Full Text] [Related]
6. Telaprevir: a new hope in the treatment of chronic hepatitis C?
Fowell AJ; Nash KL
Adv Ther; 2010 Aug; 27(8):512-22. PubMed ID: 20652658
[TBL] [Abstract][Full Text] [Related]
7. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
Bruno R; Fagiuoli S; Sacchi P
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
[No Abstract] [Full Text] [Related]
8. [Chronic hepatitis C: current treatment and perspectives].
Negro F
Rev Med Suisse; 2011 Jan; 7(279):212-3. PubMed ID: 21387717
[No Abstract] [Full Text] [Related]
9. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
10. [Hepatitis C: therapeutic perspectives].
Trépo C
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B297-302. PubMed ID: 12180304
[No Abstract] [Full Text] [Related]
11. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
12. Study Results Support Telaprevir-Based Therapy for HCV.
AIDS Patient Care STDS; 2010 Nov; 24(11):746. PubMed ID: 21108519
[No Abstract] [Full Text] [Related]
13. New developments in HCV therapy.
Kronenberger B; Zeuzem S
J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
[TBL] [Abstract][Full Text] [Related]
14. [Studies with telaprevir].
MMW Fortschr Med; 2011 Jul; 153(29-31):15. PubMed ID: 21830727
[No Abstract] [Full Text] [Related]
15. "Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors.
Lemon SM; Yi M; Li K
Hepatology; 2005 Mar; 41(3):671-4. PubMed ID: 15723328
[No Abstract] [Full Text] [Related]
16. Phase 3 study results released for telaprevir and HCV.
AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
[No Abstract] [Full Text] [Related]
17. Assessing evidence from clinical trials in chronic hepatitis C.
Bacon BR
J Viral Hepat; 2006 May; 13 Suppl 1():1-5. PubMed ID: 16630041
[TBL] [Abstract][Full Text] [Related]
18. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
Lange CM; Sarrazin C; Zeuzem S
Pharm Unserer Zeit; 2011 Jan; 40(1):60-7. PubMed ID: 21194084
[No Abstract] [Full Text] [Related]
19. The new era of hepatitis C virus therapy.
Al-Judaibi B
Saudi J Gastroenterol; 2015; 21(6):345-54. PubMed ID: 26655128
[TBL] [Abstract][Full Text] [Related]
20. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy.
Lange CM; Sarrazin C; Zeuzem S
Aliment Pharmacol Ther; 2010 Jul; 32(1):14-28. PubMed ID: 20374226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
